1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Stroke-associated	_	_	JJ	_	_	_	_	_
2	pneumonia	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	SAP	_	_	NN	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	defined	_	_	VBN	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	spectrum	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	lower	_	_	JJR	_	_	_	_	_
13	respiratory	_	_	JJ	_	_	_	_	_
14	infections	_	_	NNS	_	_	_	_	_
15	within	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	first	_	_	JJ	_	_	_	_	_
18	7	_	_	CD	_	_	_	_	_
19	days	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	stroke	_	_	NN	_	_	_	_	_
22	onset	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	one	_	_	CD	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	most	_	_	RBS	_	_	_	_	_
7	frequent	_	_	JJ	_	_	_	_	_
8	post-stroke	_	_	JJ	_	_	_	_	_
9	infections	_	_	NNS	_	_	_	_	_
10	affecting	_	_	VBG	_	_	_	_	_
11	14	_	_	CD	_	_	_	_	_
12	%	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	patients	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	associated	_	_	VBN	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	three-fold	_	_	JJ	_	_	_	_	_
21	increase	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	hospital	_	_	NN	_	_	_	_	_
24	mortality	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	prolonged	_	_	VBN	_	_	_	_	_
27	hospital	_	_	NN	_	_	_	_	_
28	stay	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	poor	_	_	JJ	_	_	_	_	_
31	functional	_	_	JJ	_	_	_	_	_
32	outcomes	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	pathophysiology	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	SAP	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	multifactorial	_	_	JJ	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_


1	Stroke	_	_	NN	_	_	_	_	_
2	induced	_	_	VBN	_	_	_	_	_
3	immunosuppression	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	aspiration	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	oropharyngeal	_	_	JJ	_	_	_	_	_
8	secretions	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	stomach	_	_	NN	_	_	_	_	_
11	contents	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	related	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	impaired	_	_	JJ	_	_	_	_	_
16	consciousness	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	dysphagia	_	_	NN	_	_	_	_	_
19	increase	_	_	VB	_	_	_	_	_
20	vulnerability	_	_	NN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	SAP	_	_	NNP	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	acute	_	_	JJ	_	_	_	_	_
26	phase	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Dysphagia	_	_	NN	_	_	_	_	_
2	occurs	_	_	VBZ	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	37	_	_	CD	_	_	_	_	_
5	â€“	_	_	TO	_	_	_	_	_
6	78	_	_	CD	_	_	_	_	_
7	%	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	stroke	_	_	NN	_	_	_	_	_
10	patients	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	increases	_	_	VBZ	_	_	_	_	_
13	risk	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	pneumonia	_	_	NN	_	_	_	_	_
16	11-fold	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	confirmed	_	_	VBN	_	_	_	_	_
21	aspiration	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	United	_	_	NNP	_	_	_	_	_
4	Kingdom	_	_	NNP	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	UK	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	national	_	_	JJ	_	_	_	_	_
10	guidelines	_	_	NNS	_	_	_	_	_
11	recommend	_	_	VBP	_	_	_	_	_
12	people	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	acute	_	_	JJ	_	_	_	_	_
15	stroke	_	_	NN	_	_	_	_	_
16	have	_	_	VBP	_	_	_	_	_
17	their	_	_	PRP$	_	_	_	_	_
18	swallow	_	_	NN	_	_	_	_	_
19	screened	_	_	VBN	_	_	_	_	_
20	within	_	_	IN	_	_	_	_	_
21	4	_	_	CD	_	_	_	_	_
22	h	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	hospital	_	_	NN	_	_	_	_	_
25	admission	_	_	NN	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	specifically	_	_	RB	_	_	_	_	_
29	trained	_	_	VBN	_	_	_	_	_
30	healthcare	_	_	NN	_	_	_	_	_
31	professional	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	if	_	_	IN	_	_	_	_	_
35	dysphagia	_	_	NN	_	_	_	_	_
36	is	_	_	VBZ	_	_	_	_	_
37	suspected	_	_	VBN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	person	_	_	NN	_	_	_	_	_
41	should	_	_	MD	_	_	_	_	_
42	have	_	_	VB	_	_	_	_	_
43	a	_	_	DT	_	_	_	_	_
44	specialist	_	_	JJ	_	_	_	_	_
45	swallow	_	_	NN	_	_	_	_	_
46	assessment	_	_	NN	_	_	_	_	_
47	by	_	_	IN	_	_	_	_	_
48	a	_	_	DT	_	_	_	_	_
49	speech	_	_	NN	_	_	_	_	_
50	and	_	_	CC	_	_	_	_	_
51	language	_	_	NN	_	_	_	_	_
52	therapist	_	_	NN	_	_	_	_	_
53	(	_	_	-LRB-	_	_	_	_	_
54	SLT	_	_	NNP	_	_	_	_	_
55	)	_	_	-RRB-	_	_	_	_	_
56	within	_	_	IN	_	_	_	_	_
57	72	_	_	CD	_	_	_	_	_
58	h	_	_	NNS	_	_	_	_	_
59	of	_	_	IN	_	_	_	_	_
60	admission	_	_	NN	_	_	_	_	_
61	(	_	_	-LRB-	_	_	_	_	_
62	Supplementary	_	_	JJ	_	_	_	_	_
63	Table	_	_	NN	_	_	_	_	_
64	S1	_	_	NN	_	_	_	_	_
65	:	_	_	:	_	_	_	_	_
66	Summary	_	_	NN	_	_	_	_	_
67	of	_	_	IN	_	_	_	_	_
68	Royal	_	_	NNP	_	_	_	_	_
69	College	_	_	NNP	_	_	_	_	_
70	of	_	_	IN	_	_	_	_	_
71	Physicians	_	_	NNP	_	_	_	_	_
72	(	_	_	-LRB-	_	_	_	_	_
73	RCP	_	_	NNP	_	_	_	_	_
74	)	_	_	-RRB-	_	_	_	_	_
75	Clinical	_	_	NNP	_	_	_	_	_
76	Guideline	_	_	NNP	_	_	_	_	_
77	for	_	_	IN	_	_	_	_	_
78	Stroke	_	_	NNP	_	_	_	_	_
79	)	_	_	-RRB-	_	_	_	_	_
80	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	increasing	_	_	VBG	_	_	_	_	_
4	evidence	_	_	NN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	early	_	_	JJ	_	_	_	_	_
7	dysphagia	_	_	NN	_	_	_	_	_
8	screening	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	associated	_	_	VBN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	reduced	_	_	VBN	_	_	_	_	_
13	odds	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	SAP	_	_	NNP	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	that	_	_	IN	_	_	_	_	_
18	delays	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	SLT	_	_	NNP	_	_	_	_	_
21	assessment	_	_	NN	_	_	_	_	_
22	increase	_	_	VBP	_	_	_	_	_
23	pneumonia	_	_	NN	_	_	_	_	_
24	incidence	_	_	NN	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	1	_	_	CD	_	_	_	_	_
27	%	_	_	NN	_	_	_	_	_
28	per	_	_	IN	_	_	_	_	_
29	day	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	delay	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	type	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	dysphagia	_	_	NN	_	_	_	_	_
5	screening	_	_	NN	_	_	_	_	_
6	protocol	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	DSP	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	used	_	_	VBN	_	_	_	_	_
11	varies	_	_	VBZ	_	_	_	_	_
12	widely	_	_	RB	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	there	_	_	EX	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	limited	_	_	JJ	_	_	_	_	_
17	information	_	_	NN	_	_	_	_	_
18	about	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	components	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	specialist	_	_	JJ	_	_	_	_	_
24	swallow	_	_	NN	_	_	_	_	_
25	assessment	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Screening	_	_	VBG	_	_	_	_	_
2	protocols	_	_	NNS	_	_	_	_	_
3	can	_	_	MD	_	_	_	_	_
4	vary	_	_	VB	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	informal	_	_	JJ	_	_	_	_	_
7	screens	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	validated	_	_	VBN	_	_	_	_	_
10	protocols	_	_	NNS	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	assess	_	_	VBP	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	water	_	_	NN	_	_	_	_	_
15	only	_	_	RB	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	stepwise	_	_	NN	_	_	_	_	_
18	screens	_	_	NNS	_	_	_	_	_
19	that	_	_	WDT	_	_	_	_	_
20	provide	_	_	VBP	_	_	_	_	_
21	separate	_	_	JJ	_	_	_	_	_
22	evaluations	_	_	NNS	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	non-fluids	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	fluids	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	RCP	_	_	NNP	_	_	_	_	_
3	Clinical	_	_	NNP	_	_	_	_	_
4	Guideline	_	_	NNP	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	Stroke	_	_	NNP	_	_	_	_	_
7	state	_	_	VBP	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	there	_	_	EX	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	good	_	_	JJ	_	_	_	_	_
12	evidence	_	_	NN	_	_	_	_	_
13	that	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	multi-item	_	_	JJ	_	_	_	_	_
16	DSP	_	_	NN	_	_	_	_	_
17	that	_	_	WDT	_	_	_	_	_
18	includes	_	_	VBZ	_	_	_	_	_
19	at	_	_	IN	_	_	_	_	_
20	least	_	_	JJS	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	water	_	_	NN	_	_	_	_	_
23	test	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	10	_	_	CD	_	_	_	_	_
26	teaspoons	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	lingual	_	_	JJ	_	_	_	_	_
30	motor	_	_	NN	_	_	_	_	_
31	test	_	_	NN	_	_	_	_	_
32	is	_	_	VBZ	_	_	_	_	_
33	more	_	_	RBR	_	_	_	_	_
34	accurate	_	_	JJ	_	_	_	_	_
35	than	_	_	IN	_	_	_	_	_
36	screening	_	_	VBG	_	_	_	_	_
37	protocols	_	_	NNS	_	_	_	_	_
38	with	_	_	IN	_	_	_	_	_
39	a	_	_	DT	_	_	_	_	_
40	single	_	_	JJ	_	_	_	_	_
41	item	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	but	_	_	CC	_	_	_	_	_
44	do	_	_	VBP	_	_	_	_	_
45	not	_	_	RB	_	_	_	_	_
46	recommend	_	_	VB	_	_	_	_	_
47	a	_	_	DT	_	_	_	_	_
48	standardised	_	_	VBN	_	_	_	_	_
49	screen	_	_	NN	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	Typically	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	swallow	_	_	NN	_	_	_	_	_
5	assessment	_	_	NN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	SLT	_	_	NNP	_	_	_	_	_
9	comprises	_	_	VBZ	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	cranial	_	_	JJ	_	_	_	_	_
12	nerve	_	_	NN	_	_	_	_	_
13	examination	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	trials	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	different	_	_	JJ	_	_	_	_	_
18	fluids	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	diet	_	_	NN	_	_	_	_	_
21	textures	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	compensatory	_	_	JJ	_	_	_	_	_
24	strategies	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Those	_	_	DT	_	_	_	_	_
2	suspected	_	_	VBN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	risk	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	aspiration	_	_	NN	_	_	_	_	_
7	should	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	assessed	_	_	VBN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	instrumental	_	_	JJ	_	_	_	_	_
12	examination	_	_	NN	_	_	_	_	_
13	using	_	_	VBG	_	_	_	_	_
14	techniques	_	_	NNS	_	_	_	_	_
15	such	_	_	JJ	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	videofluoroscopic	_	_	JJ	_	_	_	_	_
18	swallowing	_	_	NN	_	_	_	_	_
19	examination	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	VFSE	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	fibreoptic	_	_	JJ	_	_	_	_	_
25	endoscopic	_	_	JJ	_	_	_	_	_
26	evaluation	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	swallowing	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	FEES	_	_	NNS	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	assessments	_	_	NNS	_	_	_	_	_
3	provide	_	_	VBP	_	_	_	_	_
4	direct	_	_	JJ	_	_	_	_	_
5	imaging	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	assessment	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	swallowing	_	_	VBG	_	_	_	_	_
11	physiology	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	help	_	_	VB	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	predict	_	_	VB	_	_	_	_	_
16	outcomes	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	treatment	_	_	NN	_	_	_	_	_
19	planning	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	range	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	medical	_	_	JJ	_	_	_	_	_
5	interventions	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	clinical	_	_	JJ	_	_	_	_	_
8	processes	_	_	NNS	_	_	_	_	_
9	may	_	_	MD	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	associated	_	_	VBN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	risk	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	SAP	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	patients	_	_	NNS	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	dysphagia	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	emerging	_	_	VBG	_	_	_	_	_
4	evidence	_	_	NN	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	use	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	preventative	_	_	JJ	_	_	_	_	_
10	measures	_	_	NNS	_	_	_	_	_
11	such	_	_	JJ	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	screening	_	_	NN	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	stroke-induced	_	_	JJ	_	_	_	_	_
16	immunosuppression	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	dysphagia	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	identifying	_	_	VBG	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	at	_	_	IN	_	_	_	_	_
24	high	_	_	JJ	_	_	_	_	_
25	risk	_	_	NN	_	_	_	_	_
26	for	_	_	IN	_	_	_	_	_
27	SAP	_	_	NNP	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Further	_	_	JJR	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	needed	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	test	_	_	VB	_	_	_	_	_
7	this	_	_	DT	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	screening	_	_	NN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	oral	_	_	JJ	_	_	_	_	_
12	aerobic	_	_	JJ	_	_	_	_	_
13	Gram-negative	_	_	JJ	_	_	_	_	_
14	bacteria	_	_	NNS	_	_	_	_	_
15	as	_	_	RB	_	_	_	_	_
16	well	_	_	RB	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	need	_	_	NN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	evaluate	_	_	VB	_	_	_	_	_
22	if	_	_	IN	_	_	_	_	_
23	treatment	_	_	NN	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	proton	_	_	NN	_	_	_	_	_
26	pump	_	_	NN	_	_	_	_	_
27	inhibitors	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	nasogastric	_	_	JJ	_	_	_	_	_
30	tubes	_	_	NNS	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	NGT	_	_	NN	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	are	_	_	VBP	_	_	_	_	_
35	associated	_	_	VBN	_	_	_	_	_
36	with	_	_	IN	_	_	_	_	_
37	SAP	_	_	NN	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	patients	_	_	NNS	_	_	_	_	_
40	with	_	_	IN	_	_	_	_	_
41	dysphagia	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	forms	_	_	VBZ	_	_	_	_	_
4	part	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	over-arching	_	_	JJ	_	_	_	_	_
8	series	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	studies	_	_	NNS	_	_	_	_	_
11	aiming	_	_	VBG	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	explore	_	_	VB	_	_	_	_	_
14	whether	_	_	IN	_	_	_	_	_
15	variation	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	assessment	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	management	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	dysphagia	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	acute	_	_	JJ	_	_	_	_	_
24	stroke	_	_	NN	_	_	_	_	_
25	affects	_	_	VBZ	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	development	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	SAP	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Interviews	_	_	NNS	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	staff	_	_	NN	_	_	_	_	_
4	responsible	_	_	JJ	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	dysphagia	_	_	NN	_	_	_	_	_
7	screening	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	assessment	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	clinical	_	_	JJ	_	_	_	_	_
13	management	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	stroke	_	_	NN	_	_	_	_	_
16	patients	_	_	NNS	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	undertaken	_	_	VBN	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	part	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	mixed	_	_	VBN	_	_	_	_	_
24	methods	_	_	NNS	_	_	_	_	_
25	research	_	_	NN	_	_	_	_	_
26	design	_	_	NN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	inform	_	_	VB	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	development	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	national	_	_	JJ	_	_	_	_	_
34	survey	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	hospitals	_	_	NNS	_	_	_	_	_
37	registered	_	_	VBN	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	Sentinel	_	_	NNP	_	_	_	_	_
41	Stroke	_	_	NNP	_	_	_	_	_
42	National	_	_	NNP	_	_	_	_	_
43	Audit	_	_	NNP	_	_	_	_	_
44	Programme	_	_	NNP	_	_	_	_	_
45	(	_	_	-LRB-	_	_	_	_	_
46	SSNAP	_	_	NNP	_	_	_	_	_
47	)	_	_	-RRB-	_	_	_	_	_
48	database	_	_	NN	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	Statistical	_	_	JJ	_	_	_	_	_
2	analysis	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	survey	_	_	NN	_	_	_	_	_
6	responses	_	_	NNS	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	database	_	_	NN	_	_	_	_	_
10	will	_	_	MD	_	_	_	_	_
11	highlight	_	_	VB	_	_	_	_	_
12	barriers	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	facilitators	_	_	NNS	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	reducing	_	_	VBG	_	_	_	_	_
17	SAP	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	aim	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	interview	_	_	NN	_	_	_	_	_
6	study	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	explore	_	_	VB	_	_	_	_	_
10	beyond	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	4-h	_	_	NNP	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	72-h	_	_	VBG	_	_	_	_	_
15	audit	_	_	NN	_	_	_	_	_
16	criteria	_	_	NNS	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	screening	_	_	VBG	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	assessing	_	_	VBG	_	_	_	_	_
21	patients	_	_	NNS	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	dysphagia	_	_	NN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	give	_	_	VB	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	more	_	_	RBR	_	_	_	_	_
28	rounded	_	_	VBN	_	_	_	_	_
29	picture	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	care	_	_	NN	_	_	_	_	_
32	beyond	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	SSNAP	_	_	NN	_	_	_	_	_
35	performance	_	_	NN	_	_	_	_	_
36	indicators	_	_	NNS	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_

